TCH GROUP, LLC for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs; authorized generic drug provisions. H.R. 1260, Patent Reform Act of 2009; reforms of the patent laws. H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements. H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding. S. 369, Preserve Access to Affordable Generics Act: patent settlements. S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions. S. 515, Patent Reform Act of 2009: reforms of the patent laws. S. 610, Patent Reform Act of 2009: reforms of the patent laws.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Health Issues HCR
H.R. 1427, Promoting Innovations and Lifesaving Medicines Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, The Health Care and Education Reconciliation Act of 2010. S. 525, S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Issues pertaining to: prescription drug importation, comparative effectiveness, follow-on biologics, Medicare prescription drug coverage, Medicaid rebates. H.R. 444, 340B Program Improvement and Integrity Act: 340B program issues. H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation. H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness. H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness. H.R. 5710, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2010: controlled substance monitoring. H.R. 5809, Safe Drug Disposal Act of 2010: disposal of controlled substances. S. 1203, Grow Research Opportunities with Taxcredits' Help Act: R&D tax credit provisions. S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness. S. 1679, Affordable Health Choices Act: 340B program issues, importation, and other health reform implementation issues. S. 3397, Secure and Responsible Drug Disposal Act of 2010: disposal of controlled substances General FDA advocacy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Medicare/Medicaid MMM
H.R. 3590, Patient Protection and Affordable Care Act: Part D coverage gap discounts, Part D rebates, Part D issues generally, Medicare payment issues, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform fee and health reform issues generally. H.R. 4872, Healthcare & Education Reconciliation Act 2010. H.R. 4752, Medicare Prescription Drug Price Negotiation Act of 2010: Non-interference provisions. H.R. 4213, American Jobs & Closing Tax Loopholes Act of 2010: (AMP) issues. H.R. 4899, Supplemental Appropriations Act, 2010: AMP issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.